KR940014392A - 티아졸리딘디온 유도체, 그의 제조방법 및 용도 - Google Patents

티아졸리딘디온 유도체, 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR940014392A
KR940014392A KR1019930029987A KR930029987A KR940014392A KR 940014392 A KR940014392 A KR 940014392A KR 1019930029987 A KR1019930029987 A KR 1019930029987A KR 930029987 A KR930029987 A KR 930029987A KR 940014392 A KR940014392 A KR 940014392A
Authority
KR
South Korea
Prior art keywords
compound
nitrogen
general formula
thiazolidinedione
represented
Prior art date
Application number
KR1019930029987A
Other languages
English (en)
Other versions
KR100292363B1 (ko
Inventor
다까시 소다
히또시 이께다
사치꼬 이마이
유 모모세
Original Assignee
다게다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다게다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다게다 구니오
Publication of KR940014392A publication Critical patent/KR940014392A/ko
Application granted granted Critical
Publication of KR100292363B1 publication Critical patent/KR100292363B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

본 발명의 목적은 탁월한 혈당강하 및 혈중지방 강하작용을 보이는 새로운 티아졸리딘디온 유도체를 제공하는 것이다. 하기 일반식으로 표시되는 티아졸리딘디온 유도체 또는 약학적으로 허용가능한 그 염은 신규하고 탁월한 혈당 강하 및 혈중 지방 강하 작용을 보인다;
[상기 식중, n은 정수 1 내지 3을 나타내고; A는 고리성분 원자로서 하나 이상의 질소원자를 가지며, 질소에 인접한 탄소원자를 통해서 결합하며, 치환될 수도 있는 방향족 5원 헤테로시클릭고리 잔기를 나타내고; ……는 단일 또는 이중결합이다.]

Description

티아졸리딘디온 유도체, 그의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 하기 일반식으로 표시되는 티아졸리딘디온 유도체 또는 약리적으로 허용가능한 그의 염;
    [상기 식중, n은 정수 1 내지 3을 나타내고; A는 고리성분 원자로서 하나 이상의 질소원자를 가지며, 질소에 인접한 탄소원자를 통해서 결합하며, 치환될 수도 있는 방향족 5원 헤테로시클릭고리 잔기를 나타내고; ……는 단일 또는 이중결합이다.]
  2. 제1항에 있어서, n이 2인 티아졸리딘디온 유도체 또는 그의 염.
  3. 제1항에 있어서, ……가 단일 결합인 티아졸리딘디온 유도체 또는 그의 염.
  4. 제1항에 있어서, ……가 이중 결합인 티아졸리딘디온 유도체 또는 그의 염.
  5. 제1항에 있어서, 화합물이 5-[[2-[2-(5-메틸-2-페닐-4-옥사졸일)에톡시]-5-피리딜]메틸]-2, 4-티아졸리딘디온인 화합물.
  6. 제1항에 있어서, 화합물이 5-[[2-[2-(5-메틸-2-(2-나프틸)-옥사졸일)에톡시]-5-피리딜]메틸]-2, 4-티아졸리딘디온인 화합물.
  7. 제1항에 있어서, 화합물이 5-[[2-[2-(5-메틸-2-페닐-4-옥사졸일)에톡시]-5-피리딜]메틸리덴]-2, 4-티아졸리딘디온인 화합물.
  8. 활성 성분으로서 하기 일반식으로 표시되는 티아졸리딘온 유도체 또는 약리적으로 허용가능한 그 염을 함유하는 약학적 조성물;
    [상기 식중, n은 정수 1 내지 3을 나타내고; A는 고리성분 원자로서 하나 이상의 질소원자를 가지며, 질소에 인접한 탄소원자를 통해서 결합하며, 치환될 수도 있는 방향족 5원 헤테로시클릭고리 잔기를 나타내고; ……는 단일 또는 이중결합이다.]
  9. 제8항에 있어서, 조성물이 당뇨병 또는 지방과잉증에 대한 치료제인 약학적 조성물.
  10. 하기 일반식으로 표시되는 아미노티아졸리딘은 화합물(Ⅱ)을 가수분해함을 특징으로 하는 하기 일반식으로 표시되는 티아졸리딘디온 유도체(Ⅰ-Ⅰ)의 제조방법;
    [상기 식중 n은 1내지 3의 정수를 나타내고; A는 고리성분 원자로서 하나 이상의 질소원자를 가지며, 질소에 인접한 탄소원자를 통해서 결합하며, 치환될 수도 있는 방향족 5원 헤테로시클릭고리 잔기를 나타낸다.]
    [상기 식중, 기호는 상기 정의와 동일하다.]
  11. 하기 일반식으로 표시되는 화합물(Ⅲ)과 2, 4-티아졸리딘디온을 축합시키고, 필요하다면 이 생성 화합물을 환원시키는 것을 특징으로 하는 하기 일반식으로 표시된 티아졸리딘디온 유도체(Ⅰ)의 제조방법;
    [상기 식중, n은 정수 1 내지 3을 나타내고; A는 고리성분 원자로서 하나 이상의 질소원자를 가지며, 질소에 인접한 탄소원자를 통해서 결합하며, 치환될 수 도 있는 방향족 5원 헤테로시클릭고리 잔기를 나타내고: ……는 단일 또는 이중결합이다.]
    [상기 식중, 기호는 상기 정의와 동일하다.]
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930029987A 1992-12-28 1993-12-27 티아졸리딘디온유도체,그의제조방법및용도 KR100292363B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34856892 1992-12-28
JP92-348568 1992-12-28
JP18099693 1993-07-22
JP93-180996 1993-07-23

Publications (2)

Publication Number Publication Date
KR940014392A true KR940014392A (ko) 1994-07-18
KR100292363B1 KR100292363B1 (ko) 2001-09-17

Family

ID=26500340

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930029987A KR100292363B1 (ko) 1992-12-28 1993-12-27 티아졸리딘디온유도체,그의제조방법및용도

Country Status (21)

Country Link
US (1) US5489602A (ko)
EP (1) EP0605228B1 (ko)
JP (1) JP3741452B2 (ko)
KR (1) KR100292363B1 (ko)
CN (1) CN1056372C (ko)
AT (1) ATE190052T1 (ko)
AU (1) AU666414B2 (ko)
CA (1) CA2112283A1 (ko)
CZ (1) CZ288363B6 (ko)
DE (1) DE69327944T2 (ko)
DK (1) DK0605228T3 (ko)
ES (1) ES2142852T3 (ko)
FI (1) FI935887A (ko)
GR (1) GR3033487T3 (ko)
HU (1) HUT69383A (ko)
MX (1) MX9400190A (ko)
MY (1) MY110142A (ko)
NO (1) NO300735B1 (ko)
PT (1) PT605228E (ko)
RU (1) RU2129553C1 (ko)
TW (1) TW245716B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420669B (en) * 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5965589A (en) * 1994-08-10 1999-10-12 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
WO1997041120A1 (en) * 1996-07-26 1997-11-06 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
WO1997041119A1 (en) * 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
WO2004100895A2 (en) * 2003-05-13 2004-11-25 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2516425B1 (en) * 2009-12-23 2015-09-02 Jasco Pharmaceuticals LLC Aminopyrimidine kinase inhibitors
CN101824032B (zh) * 2010-04-23 2015-09-09 浙江华海药业股份有限公司 一种制备盐酸吡格列酮的工艺改进方法
CN104011046B (zh) 2011-11-04 2017-05-03 嘉世高制药公司 氨基嘧啶激酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5364586A (en) * 1976-11-19 1978-06-09 Takeda Chemical Industries Ltd Emission driving device for blood detector
JPS5564586A (en) * 1978-11-09 1980-05-15 Takeda Chem Ind Ltd Thiazolidine derivative
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US5130379A (en) * 1988-03-08 1992-07-14 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives

Also Published As

Publication number Publication date
GR3033487T3 (en) 2000-09-29
NO934833D0 (no) 1993-12-27
CZ287693A3 (en) 1994-12-15
ES2142852T3 (es) 2000-05-01
KR100292363B1 (ko) 2001-09-17
JPH0782269A (ja) 1995-03-28
CA2112283A1 (en) 1994-06-29
DE69327944T2 (de) 2000-10-19
HUT69383A (en) 1995-09-28
EP0605228A1 (en) 1994-07-06
US5489602A (en) 1996-02-06
CN1056372C (zh) 2000-09-13
RU2129553C1 (ru) 1999-04-27
FI935887A (fi) 1994-06-29
HU9303757D0 (en) 1994-04-28
ATE190052T1 (de) 2000-03-15
AU666414B2 (en) 1996-02-08
DK0605228T3 (da) 2000-06-05
NO300735B1 (no) 1997-07-14
JP3741452B2 (ja) 2006-02-01
CZ288363B6 (en) 2001-06-13
FI935887A0 (fi) 1993-12-27
NO934833L (no) 1994-06-29
MY110142A (en) 1998-02-28
TW245716B (ko) 1995-04-21
MX9400190A (es) 1994-07-29
DE69327944D1 (de) 2000-04-06
AU5261393A (en) 1994-07-07
PT605228E (pt) 2000-06-30
CN1094726A (zh) 1994-11-09
EP0605228B1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
KR940014392A (ko) 티아졸리딘디온 유도체, 그의 제조방법 및 용도
KR890005095A (ko) 신규 화합물들
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
KR930702287A (ko) 신규화합물
KR930701434A (ko) 옥사졸리딘 디온 유도체
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
KR880011153A (ko) 벤즈옥사졸 유도체 및 이의 제조방법
KR910004580A (ko) 신규 화합물
KR970000233A (ko) 약제학적 조성물
ATE293611T1 (de) Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren
AR012250A1 (es) Derivados de 2-(iminometil)amino-fenilo, procedimientos para su preparacion, intermediarios utilizados en dichos procedimientos, medicamento y composicion farmaceutica que contienen a dichos derivados y uso de estos derivados para manufacturar un medicamento
KR960702460A (ko) 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them)
RU96124376A (ru) Применение производных тиазолидина для лечения и профилактики остеопороза
UY25227A1 (es) Procedimiento para preparar 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-2,4-tiazolidindiona
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
KR970707122A (ko) 퀴놀린 유도체(quinoline derivative)
KR910011817A (ko) 중추 신경계 약제로서 유용한 치환 시클로헥센
AU1916895A (en) Thiazolidinedione derivatives as anti-hyperglycemic agents
ATE269862T1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
KR970032864A (ko) 골다공증 치료제
RU97104022A (ru) Применение инсулинового сенсибилизатора для лечения и профилактики панкреатита
KR940018386A (ko) 티오펜 화합물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee